Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS

Leukemia Research

Volumn 36, Issue 1, 2012, Pages 1-5

  Valent, Peter ^a,b   Bain, Barbara J ^c   Bennett, John M ^d   Wimazal, Friedrich ^a,e   Sperr, Wolfgang R ^a,b   Mufti, Ghulam ^f   Horny, Hans Peter ^g  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c Medicine   (United Kingdom)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g Institute of Pathology Ansbach   (Germany)

Author keywords

Diagnostic criteria; ICUS; IDUS; MDS; Pre malignant lesions

Indexed keywords

HEMOGLOBIN;

ACUTE GRANULOCYTIC LEUKEMIA; BLOOD ANALYSIS; BONE MARROW BIOPSY; BONE MARROW CELL; BONE MARROW DISEASE; CYTOPENIA; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; FLOW CYTOMETRY; FOLLOW UP; HUMAN; IDIOPATHIC ANEMIA OF UNCERTAIN SIGNIFICANCE; IDIOPATHIC CYTOPENIA OF UNDETERMINED SIGNIFICANCE; IDIOPATHIC DYSPLASIA OF UNCERTAIN SIGNIFICANCE; IDIOPATHIC NEUTROPENIA OF UNCERTAIN SIGNIFICANCE; IDIOPATHIC PANCYTOPENIA OF UNCERTAIN SIGNIFICANCE; IDIOPATHIC THROMBOCYTOPENIA OF UNCERTAIN SIGNIFICANCE; KARYOTYPING; MASTOCYTOSIS; MYELODYSPLASTIC SYNDROME; NEUTROPHIL COUNT; PREDICTION; PRIORITY JOURNAL; REVIEW; THROMBOCYTE COUNT;

DIAGNOSIS, DIFFERENTIAL; HUMANS; LEUKOPENIA; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 83555162627     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.08.016     Document Type: Review

References (26)

1. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982, 51:189-199.
2. Bennett J.M., Komrokji R.S. The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment. Hematology 2005, 10:258-269.
3. Nimer S.D. Myelodysplastic syndromes. Blood 2008, 111:4841-4851.
4. Brunning R.D., Orazi A., Germing U., Le Beau M.M., Porwit A., Baumann I., et al. Myelodysplastic syndromes/neoplasms. World Health Organization classification of tumours. Pathology & genetics. Tumours of haematopoietic and lymphoid tissues 2008, 2:88-107. IARC Press, Lyon.
5. Orazi A., Czader M.B. Myelodysplastic syndromes. Am J Clin Pathol 2009, 132:290-305.
6. Valent P., Horny H.-P., Bennett J.M., Fonatsch C., Germing U., Greenberg P., et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007, 31:727-736.
7. Bain B.J. Problems in the morphological diagnosis of MDS. Satellite symposium: an evolution in the understanding of myelodysplastic syndromes, European Society for Hematology June 15 2006.
8. Mufti G.J., Bennett J.M., Goasguen J., Bain B.J., Baumann I., Brunning R., et al. Minimal diagnostic criteria and differential diagnosis of MDS: IWGM-MDS consensus proposal for identification of idiopathic cytopenia of uncertain significance (ICUS). Paper presented at the 9th international symposium on myelodysplastic syndromes 2007.
9. van de Loosdrecht A.A., Alhan C., Béné M.C., Della Porta M.G., Dräger A.M., Feuillard J., et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica 2009, 94:1124-1134.
10. Orazi A. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases. Pathobiology 2007, 74:97-114.
11. Horny H.P., Sotlar K., Valent P. Diagnostic value of histology and immunohistochemistry in myelodysplastic syndromes. Leuk Res 2007, 31:1609-1616.
12. Bennett J.M., Orazi A. Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach. Haematologica 2009, 94:264-268.
13. Valent P., Orazi A., Büsche G., Schmitt-Gräff A., George T.I., Sotlar K., et al. Standards and impact of hematopathology in myelodysplastic syndromes (MDS). Oncotarget 2010, 1:483-496.
14. Wimazal F., Fonatsch C., Thalhammer R., Schwarzinger I., Müllauer L., Sperr W.R., et al. Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface. Leuk Res 2007, 31:1461-1468.
15. Valent P., Horny H.P. Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions. Eur J Clin Invest 2009, 39:548-553.
16. Schroeder T., Ruf L., Bernhardt A., Hildebrandt B., Aivado M., Aul C., et al. Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients. Ann Oncol 2010, 21:2267-2271.
17. Ando K., Tanaka Y., Hashimoto Y., Ohyashiki J.H., Sugimori N., Nakao S., et al. PNH-phenotype cells in patients with idiopathic cytopenia of undetermined significance (ICUS) with megakaryocytic hypoplasia and thrombocytopenia. Br J Haematol 2010, 150:705-707.
18. Valent P. Low erythropoietin production as non-oncogenic co-factor contributing to disease-manifestation in low-risk MDS: a hypothesis supported by unique case reports. Leuk Res 2008, 32:1333-1337.
19. Valent P., Jäger E., Mitterbauer-Hohendanner G., Müllauer L., Schwarzinger I., Sperr W.R., et al. Idiopathic bone marrow dysplasia of unknown significance (IDUS): definition, pathogenesis, follow up, and prognosis. Am J Cancer Res 2011, 1:531-541.
20. Valent P., Fonatsch C., Stindl R., Schwarzinger I., Haas O.A., Sperr W.R., et al. Normal bone marrow function over 6 years in a patient with dysplastic hematopoiesis and a complex karyotype. Leuk Res 2004, 28:651-655.
21. Ferrucci L., Guralnik J.M., Bandinelli S., Semba R.D., Lauretani F., Corsi A., et al. Unexplained anaemia in older persons is characterised by low erythropoietin and low levels of pro-inflammatory markers. Br J Haematol 2007, 136:849-855.
22. Valent P. Anaemia of the elderly (AOE): does it exist and does it matter in clinical practice?. Eur J Clin Invest 2008, 38:782-783.
23. Hellström-Lindberg E., Negrin R., Stein R., Krantz S., Lindberg G., Vardiman J., et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 1997, 99:344-351.
24. Hellström-Lindberg E., Malcovati L. Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes. Semin Hematol 2008, 45:14-22.
25. Westers T.M., Alhan C., Chamuleau M.E., van der Vorst M.J., Eeltink C., Ossenkoppele G.J., et al. Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment. Blood 2010, 115:1779-1784.
26. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.